Inhibicion de la Angiogénesis en pTNEs - page 21

Sunitinib en

TNEs

G1/G2

Safety & QOL

ViniK A, et al. Targ Oncol 2016

Median TTD (months)

Sunitinib

Placebo

*P<0.05 vs placebo; log-rank test

TTD = time to deterioration

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1...,11,12,13,14,15,16,17,18,19,20 22,23,24,25,26,27,28,29,30,31,...36